

FY 2023 – H1 2024 Clinical CRO Market

Highlights, Trends, Opportunities & Outlook


Reach the Right Outcome

www.outcomecapital.com



Pharma Services Focusing In On Phase I-IV Clinical Trials

FY 2023 – H1 2024 Clinical CRO Market



Clinical Offerings Usher Technologies From Target Discovery To Commercial-Ready

2



Growing Pharma Innovation Underpins Clinical CRO Segment FY 2023 – H1 2024 Clinical CRO Market

Global Clinical CRO Market

Contract service providers for involved in later stages of drug development, including clinical trial design & management, data analysis & pharmacovigilance



Market Dynamics

- >50% of clinical processes outsourced due to high-costs associated with in-house drug development
- Decline in clinical trial starts (~15% from 2022-2023) primarily due to fewer multi-study trials conducted by strategics
- Increasing R&D investment to bolster pipelines as well as growing focus on precision medicine requires specialized expertise
- CROs typically faster to adopt digitized, Alenabled & analytical technologies for R&D; opportunity to leverage these technologies for streamlined development with minimal investment
- Opportunity for CROs to develop techenabled solutions for decentralized & remote trials, increased patient engagement & streamlined patient recruitment


Strong R&D Pipelines & Expedited Timelines Support Demand For Outsourced Clinical Services

Sources: PitchBook, Vial, Clinical Research News, PharmaExec.com, IQVIA



Platforms Seek Specialized Capabilities & Expanded Capacity

FY 2023 – H1 2024 Clinical CRO Market



Key Highlights

- Uptick in transaction activity in FY23 as platforms continue to bolster capabilities as well as geographic footprint
- H1/24 experiencing slowdown in transactions as key buyers continue to integrate targets from recent deals
- Strategic & financial acquirers expected to add-on adjacent targets to support end-to-end service providers

"

Clinical trial sites are undoubtedly the hottest category of pharma services as previously [physician practice management]-focused firms pivot into the life sciences category closest to their historical area of expertise...Research Network, both of which closed in late 2023. Given that the trial site niche is still fragmented, there's plenty of room for M&A activity, according to the analysis.



Acquirers In Process Of Integrating Recent Targets; Anticipating Uptick In Tuck-In M&A To Differentiate Capabilities

Sources: PitchBook, Informa Connect, Fierce Biotech, Company Press Releases

23



Private Equity Continue Platform-Building Strategies

FY 2023 – H1 2024 Clinical CRO Market

CRO Platform		HEALTH INVESTORS Acquirer	NOVOTEC CRO Platform	H	Acquirer
Target	Deal Date	Description Biometrics-specialized	Target	Deal Date	Description Regulatory consulting
clinical research	10/1/2023	clinical CRO focused on biotech & medical devices	CBR INTERNATIONAL	1/9/2023	group servicing pharma companies navigate the FDA approval process
SCINOPSIS MEDICAL WRITING	6/12/2023	European-based medical writing consultancy focused on regulatory & medical communications	R e h s t HORN	1/9/2023	Clinical CRO focused on providing clinical trial services across Europe

Private Equity CRO Platforms Expand Capabilities Via Geographic Presence & Niche Tuck-In Capabilities

Sources: PitchBook, Vial, Clinical Research News, PharmaExec.com, IQVIA



Buyouts Of Clinical Service Leaders Likely To Spur Future M&A

FY 2023 – H1 2024 Clinical CRO Market

Date	Target	Buyer	Target Description		Transaction Insights
05/13/2024	nirom group	Blackstone	Japanese healthcare entity spanning four business units: Advanced Medicinal Treatment, CRO, Site Management Organization, and Medical Support	•	Targeting new therapeutic area expansion through tuck-in transactions
08/07/2023	WORLDWIDE CLINICAL TRIALS	KOHLBERG & C O M P A N Y	Global CRO providing bioanalytical & clinical solutions across a variety of disease areas including cardiovascular, metabolic, and neuroscience		Decentralized Clinical Trial expertise enhances position as M&A target Profitability is key criteria for
05/10/2023	Syneos Health	ELLIOTT PATIENT CAPITAL CAPITAL	Biopharmaceutical solutions organization providing clinical development, medical affairs, commercial delivery, and consulting services		private equity firms evaluating platform targets Clinical trial sites garnering interest to enhance operational
01/10/2023	CLINICAL SERVICES	NOVOTECH The Asia Pacific CRO	European CRO with broad disease area coverage (oncology, cardiology, CNS, etc.) while leveraging local expertise in 20 countries	•	capacity as well as commercial footprint Acquirers seeking to create value through specialized
01/03/2023	> PHARMALEX	cencora	Global pharma solutions organization focusing on strategic planning, preclinical & clinical development, regulatory affairs, and commercialization		service add-ons with efficient timelines

Recent Platform Formation Provides Foundation For Near-Term Expansion In New Therapeutic Areas

Sources: Company Press Releases

Complementary & Data-Enabled Services Garner Investor Interest

FY 2023 – H1 2024 Clinical CRO Market

Date Target	Investor(s)	Target Description	
	Taimei _{太美医疗科技}	CRO providing clinical research services including real-world research to help streamline drug development for expedited launch	• T c r
12/14/2023	Marula Square	CRO providing real-world data, analytics, visualization, commercialization, and patient management services to pharmaceutical companies	c ir • (
06/30/2023 PHARMASEAL	Undisclosed	Developer of unified clinical trial management & control platform for biopharma, medical devices, animal health, and CROs	• L
05/18/2023 至 減 服 务 · 健 康 中 国	中指建校派券股份有限公司 CSC FINANCIAL CO., LTD.	Provider of phase I-IV clinical contract research services for pharmaceutical & medical device companies	
03/30/2023 (①) 青莲百奥 QL Bio	德联资本 Delian Capital	Provider of systems biology services including research, pharmaceutical, translational medicine, and bid data processing	si h

Transaction Insights

- Targets offering services in complementary areas (i.e., regulatory, real-world evidence, data analytics, etc.)garnering investor interest
- Clinical service providers seeking to develop trial management offerings as opportunity for differentiation
- Leveraging investment capital to continue capability development with emphasis on data-enabled solutions to drive value
- Development of differentiated solutions prime clinical CROs for high-value exit

Targets Offering Differentiated Capabilities & Upstream/Downstream Services Prime For Future M&A

Sources: Company Press Releases



Global Platform Creation Through Syneos Acquisition

FY 2023 - H1 2024 Clinical CRO Market



Target Description: Biopharmaceutical solutions organization providing clinical development, medical affairs, commercial delivery, and consulting services

Transaction Structure & Overview

- Take-private transaction valuing Syneos at \$7.1B including outstanding debt
- \$43/share all-cash offer represents 24% premium to the trading price prior to the announcement of the acquisition

Outcome Strategic Insights

In May 2017 InVentiv Health and INC Research Holdings merged to become Syneos Health (Nasdaq: SYNH), a global CRO valued at ~\$7.1B. The completion of this transaction has been a long time coming, as the company has been looking for a suitor since 2020. This transaction should provide more flexibility for Syneos to make strategic investments to grow and expand their business, without the watchful eye of Wall St.

Financial buyers have focused on the Clinical CRO sector, as both pharma and biotech continue to outsource clinical trials due to the increasing complexity and costs. This transaction is a prime example how the

allure of Wall St. can hinder a company's growth. Focusing on quarterly earnings and short-term plans to maintain status in the public markets can come at the expense of long-term growth and investment. Let's see how Syneos and the new team can grow this business in the coming years.



Craig Steger Outcome Capital, LLC csteger@outcomecapital.com


Take-Private Transaction Enables High-Growth Global Growth Strategy In Tech-Enabled Late-Stage Clinical Trials

"

Outcome Capital Overview

FY 2023 – H1 2024 Clinical CRO Market

Outcome Capital is a **highly-specialized life sciences & healthcare-dedicated** investment banking & strategic advisory firm adopting a unique **market-driven**, **strategy-led** approach to value enhancement. Our team consists of industry veterans with broad **entrepreneurial**, **strategic & operational expertise with deep scientific**, **clinical & financial expertise**.





Outcome Capital Pharma Services Report Authors



Craig Steger Managing Director Csteger@outcomecapital.com



Nicholas Frame, PhD Senior Vice President Nframe@outcomecapital.com



Elena Bonetti Senior Analyst Ebonetti@outcomecapital.com



Curtis Landry Analyst Clandry@outcomecapital.com



Oded Ben-Joseph, PhD, MBA Managing Partner Oben-joseph@outcomecapital.com



20 Custom House Street Suite 1200 Boston, MA 02110 (617) 431-2278



Reach the Right Outcome